This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Hypertension  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

The Next Treatable, Silent Killer?

Julius M. Gardin, MD; Michael S. Lauer, MD

JAMA. 2004;292:2396-2398.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

An increase in the mass of left ventricular muscle is intimately associated with most chronic diseases of the heart.^1-6 Classically, left ventricular hypertrophy, which represents an extreme increase in left ventricular mass, has been thought to represent a reaction to pressure or volume overload.^7-8 In the short run, increases in left ventricular mass may be beneficial by allowing the heart to compensate for increased wall stress and potential hemodynamic compromise; in the long run, left ventricular hypertrophy is harmful.⁸

Although the development of left ventricular hypertrophy has been related to a number of conditions,⁴ including obesity,⁹ diabetes,¹⁰ prior myocardial infarction,¹¹ aortic stenosis,¹² and regurgitant valvular heart disease,¹² hypertension may well be the condition about which the most is known.¹³ Data from the Framingham Heart Study have shown that even mild increases in blood pressure are associated with increased left ventricular mass.¹⁴ Furthermore, . . . [Full Text of this Article]

Author Affiliations: Division of Cardiology, St John Hospital & Medical Center, Detroit, Mich (Dr Gardin), and Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Lauer). Dr Lauer is also Contributing Editor, JAMA.

RELATED ARTICLES

Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events
Peter M. Okin, Richard B. Devereux, Sverker Jern, Sverre E. Kjeldsen, Stevo Julius, Markku S. Nieminen, Steven Snapinn, Katherine E. Harris, Peter Aurup, Jonathan M. Edelman, Hans Wedel, Lars H. Lindholm, Björn Dahlöf, and for the LIFE Study Investigators
JAMA. 2004;292(19):2343-2349.
ABSTRACT | FULL TEXT  

Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension
Richard B. Devereux, Kristian Wachtell, Eva Gerdts, Kurt Boman, Markku S. Nieminen, Vasilios Papademetriou, Jens Rokkedal, Katherine Harris, Peter Aurup, and Björn Dahlöf
JAMA. 2004;292(19):2350-2356.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reversibility of Cardiac Abnormalities in Morbidly Obese Adolescents
Ippisch et al.
J Am Coll Cardiol 2008;51:1342-1348.
ABSTRACT | FULL TEXT  

Requirement of protein kinase D1 for pathological cardiac remodeling
Fielitz et al.
Proc. Natl. Acad. Sci. USA 2008;105:3059-3063.
ABSTRACT | FULL TEXT  

Regulation of Cardiac Stress Signaling by Protein Kinase D1
Harrison et al.
Mol. Cell. Biol. 2006;26:3875-3888.
ABSTRACT | FULL TEXT  

Regression of LV Hypertrophy in Hypertensive Patients
Journal Watch Cardiology 2004;2004:1-1.
FULL TEXT